Romosozumab-aqqg 89.7 mg/ML in 1.17 mL Prefilled Syringe 2-Pack (210 mg Dose)
RxNorm 2123185

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2123185 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: romosozumab-aqqg 89.7 mg/ML in 1.17 mL Prefilled Syringe 2-Pack (210 mg Dose).

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Romosozumab-aqqg 89.7 mg/ML in 1.17 mL Prefilled Syringe 2-Pack (210 mg Dose)
AUI:10896936
View
GPCK
{2 (1.17 mL romosozumab-aqqg 89.7 mg/ML Prefilled Syringe) } Pack
AUI:10896908
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Romosozumab-aqqg 89.7 mg/ML in 1.17 mL Prefilled Syringe 2-Pack (210 mg Dose)
(Atom ID: 10896936)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
romosozumab-aqqg 89.7 MG/ML in 1.17 ML Prefilled Syringe 2-Pack (210 MG Dose)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2123185
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10896936
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2123185
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
GPCKPrescribable

Generic Pack (GPCK):
{2 (1.17 mL romosozumab-aqqg 89.7 mg/ML Prefilled Syringe) } Pack
(Atom ID: 10896908)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{2 (1.17 ML romosozumab-aqqg 89.7 MG/ML Prefilled Syringe) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2123185
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10896908
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
2123185
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Romosozumab-aqqg Injection


Romosozumab-aqqg injection is used to treat osteoporosis (condition in which the bones become thin and weak and break easily) in postmenopausal women (women who have experienced a change of life; end of menstrual periods) who have a high risk of a fracture or when other osteoporosis treatments did not help or could not be tolerated. Romosozumab-aqqg injection is in a class of medications called monoclonal antibodies. It works by increasing bone formation and decreasing bone breakdown.
[Learn More]


* Please review the disclaimer below.